Abstract: The present invention discloses an immediate release tablet comprising at least a tablet core, wherein the tablet core comprises at most 20% brexpiprazole relative to the total of the tablet core, and at least one pharmaceutically acceptable excipient, wherein the tablet core is made by direct compression. Also disclosed are a batch of such immediate release tablets, and a process for preparing such immediate release tablets.

Abstract: The present invention discloses possibilities to make use of a substance or a material arranged to block, absorb and/or reflect UV exposure of a certain wavelength region to reduce or prevent UV-induced dimerization and optionally further UV-induced brexpiprazole impurities of brexpiprazole in a brexpiprazole dihydrate comprising pharmaceutical composition.

Abstract: The present invention discloses an immediate release tablet comprising at least a tablet core, wherein the tablet core comprises at most 20% brexpiprazole relative to the total of the tablet core, and at least one pharmaceutically acceptable excipient, wherein the tablet core is made by direct compression. Also disclosed are a batch of such immediate release tablets, and a process for preparing such immediate release tablets.

Abstract: The present invention relates to a solid oral pharmaceutical composition comprising vortioxetine hydrobromide in a matrix formed from at least one polyethylene oxide and optionally one or more further matrix forming polymers.

Abstract: The present invention relates to a solid oral pharmaceutical composition comprising vortioxetine hydrobromide in a matrix formed from at least one polyethylene oxide and optionally one or more further matrix forming polymers.

Abstract: The present invention relates to an oral pharmaceutical composition comprising dabigatran etexilate or a pharmaceutically acceptable salt thereof, methods for preparing it and dosage forms for oral administration comprising said composition. The pharmaceutical composition is particularly useful as a medicament, especially as anticoagulant.

Abstract: The invention relates to a process for preparing a composition, more particularly a pharmaceutical composition for oral administration, comprising the steps of forming a suspension of at least one pharmaceutical ingredient and a solvent or solvent mixture, the at least one pharmaceutical ingredient being insoluble or poorly soluble in the solvent or solvent mixture, the step of adding at least one gel former to the suspension, the at least one gel former being swellable in the solvent or solvent mixture, and, optionally, the step of swelling the suspension.